| Literature DB >> 29414106 |
Lucie Raisová Stuchlíková1, Petra Matoušková1, Ivan Vokřál2, Jiří Lamka2, Barbora Szotáková1, Anna Sečkařová1, Diana Dimunová1, Linh Thuy Nguyen1, Marián Várady3, Lenka Skálová4.
Abstract
<span class="Species">Haemonchus contortus (family Trichostrongylidae, Nematoda), a <span class="Disease">hematophagous gastrointestinal parasite found in small ruminants, has a great ability to develop resistance to anthelmintic drugs. We studied the biotransformation of the three benzimidazole anthelmintics: albendazole (ABZ), ricobendazole (albendazole S-oxide; RCB) and flubendazole (FLU) in females and males of H. contortus in both a susceptible ISE strain and resistant IRE strain. The ex vivo cultivation of living nematodes in culture medium with or without the anthelmintics was used. Ultrasensitive UHPLC/MS/MS analysis revealed 9, 7 and 12 metabolites of ABZ, RCB and FLU, respectively, with most of these metabolites now described in the present study for the first time in H. contortus. The structure of certain metabolites shows the presence of biotransformation reactions not previously reported in nematodes. There were significant qualitative and semi-quantitative differences in the metabolites formed by male and female worms. In most cases, females metabolized drugs more extensively than males. Adults of the IRE strain were able to form many more metabolites of all the drugs than adults of the ISE strain. Some metabolites were even found only in adults of the IRE strain. These findings suggest that increased drug metabolism may play a role in resistance to benzimidazole drugs in H. contortus.Entities:
Keywords: Anthelmintics; Benzimidazole; Drug metabolism; Drug resistance; Nematode
Mesh:
Substances:
Year: 2018 PMID: 29414106 PMCID: PMC6114105 DOI: 10.1016/j.ijpddr.2018.01.005
Source DB: PubMed Journal: Int J Parasitol Drugs Drug Resist ISSN: 2211-3207 Impact factor: 4.077
List of main peaks for FLU biotransformation samples detected by UHPLC-MS/MS with their retention times, theoretical values of [M+H]+ ions in ESI positive-ion mode, elemental composition, product ions, and description of present metabolites.
| tR [min] | Theoretical | Elemental composition | Description of metabolite formation | Product ions of [M+H]+, | Metabolite designation | |
|---|---|---|---|---|---|---|
| Phase I | Phase II | |||||
| 3.22 | 418.14 | C20H20FN3O6 | Hydrolysis | 256, 123 | M1FLU | |
| 3.31 | 478.16 | C22H24FN3O8 | Carbonyl reduction | 316, 284 | M2FLU | |
| 3.42 | 478.16 | C22H24FN3O8 | Carbonyl reduction | 298, 266 | M3FLU | |
| 3.58 | 478.16 | C22H24FN3O8 | Carbonyl reduction | 298, 266 | M4FLU | |
| 3.7 | 418.14 | C20H20FN3O6 | Hydrolysis | 256 | M5FLU | |
| 3.82 | 478.16 | C22H24FN3O8 | Carbonyl reduction | 298, 266 | M6FLU | |
| 4.04 | 478.16 | C22H24FN3O8 | Carbonyl reduction | 316, 284 | M7FLU | |
| 4.8 | 316.10 | C16H14FN3O3 | Carbonyl reduction | – | 284, 238 | M8FLU |
| 5.33 | 476.14 | C22H22FN3O8 | – | 314, 282, 123 | M9FLU | |
| 5.44 | 330.12 | C17H16FN3O3 | Carbonyl reduction | Methylation | 298, 174 | M10FLU |
| 5.52 | 476.14 | C22H22FN3O8 | Hydrolysis, hydroxylation | Glycosidation, O-acetylation | 256 | M11FLU |
| 5.62 | 476.14 | C22H22FN3O8 | – | 314, 282, 123 | M12FLU | |
| 8.27 | 314.09 | C16H12FN3O3 | – | 282, 123 | FLU (parent drug) | |
Presence (+) or absence (−) of FLU metabolites in homogenates and medium of H. contortus females and males from ISE and IRE strains.
| Metabolite designation | Homogenate of | Medium | ||||||
|---|---|---|---|---|---|---|---|---|
| ISE | IRE | ISE | IRE | |||||
| Females | Males | Females | Males | Females | Males | Females | Males | |
| M1FLU | – | – | – | – | – | – | + | – |
| M2FLU | – | – | – | – | – | – | + | – |
| M3FLU | – | – | + | – | – | – | + | + |
| M4FLU | + | + | + | + | + | + | + | + |
| M5FLU | – | – | + | + | + | + | + | + |
| M6FLU | – | – | – | – | – | – | + | – |
| M7FLU | – | – | + | – | + | – | + | – |
| M8FLU | + | + | + | + | + | + | + | + |
| M9FLU | – | – | + | – | – | – | + | – |
| M10FLU | – | – | + | – | – | – | + | + |
| M11FLU | + | + | + | + | + | + | + | + |
| M12FLU | + | + | + | + | + | + | + | + |
| FLU (parent drug) | + | + | + | + | + | + | + | + |
Fig. 1The proposed metabolic pathway of FLU in H. contortus adults.
Fig. 2Changes in the relative amount of the main FLU metabolites M8FLU (FLU-R; Fig. 6a) and M4FLU (FLU-R O-glycoside, Fig. 6b) in worm homogenates and medium from females and males of the susceptible ISE strain and resistant IRE strain. The data represent the mean ± S.D. (n = 3). IS = internal standard.
Fig. 6Changes in the relative amount of the main RCB metabolites M7RCB (ABZ, S-oxide reduction of RCB; Fig. 4a) and M5RCB (glycoside of M7RCB, Fig. 4b) in worm homogenates and medium from females and males of susceptible ISE strain and resistant IRE strain. The data represent the mean ± S.D. (n = 3). IS = internal standard.
List of main peaks for ABZ biotransformation samples detected by UHPLC-MS/MS with their retention times, theoretical values of [M+H]+ ions in ESI positive-ion mode, elemental composition, product ions, and description of present metabolites.
| tR [min] | Theoretical | Elemental composition | Description of metabolite formation | Product ions of [M+H]+, | Metabolite designation | |
|---|---|---|---|---|---|---|
| Phase I | Phase II | |||||
| 1.83 | 444.14 | C18H25N3O8S | S-oxidation | 282, 240, 208, 191, 159 | M1ABZ | |
| 2.33 | 444.14 | C18H25N3O8S | S-oxidation | 282, 240, 208 | M2ABZ | |
| 3.32 | 282.09 | C12H15N3O3S | S-oxidation | – | 240, 208, 191,159 | M3ABZ |
| 3.56 | 370.14 | C16H23N3O5S | Hydrolysis | 208 | M4ABZ | |
| 4.53 | 370.14 | C16H23N3O5S | Hydrolysis | 208 | M5ABZ | |
| 5.22 | 298.09 | C12H15N3O4S | 2*S-oxidation | – | 266, 224, 159 | M6ABZ |
| 5.65 | 428.15 | C18H25N3O7S | – | 266, 234, 191 | M7ABZ | |
| 6.16 | 428.15 | C18H25N3O7S | – | 266, 234 | M8ABZ | |
| 6.71 | 428.15 | C18H25N3O7S | – | 266, 234 | M9ABZ | |
| 7.5 | 266.10 | C12H15N3O2S | – | – | 234 | ABZ (parent drug) |
Presence (+) or absence (−) of ABZ metabolites in homogenates and medium of H. contortus females and males from ISE and IRE strains.
| Metabolite designation | Homogenate of | Medium | ||||||
|---|---|---|---|---|---|---|---|---|
| ISE | IRE | ISE | IRE | |||||
| Females | Males | Females | Males | Females | Males | Females | Males | |
| M1ABZ | – | – | + | + | – | – | – | – |
| M2ABZ | – | – | + | + | – | + | + | + |
| M3ABZ | + | + | + | + | + | + | + | + |
| M4ABZ | – | – | – | – | + | + | + | + |
| M5ABZ | – | – | + | – | – | – | + | – |
| M6ABZ | + | + | + | + | + | + | + | + |
| M7ABZ | + | + | + | + | + | + | + | + |
| M8ABZ | + | + | + | + | + | + | + | + |
| M9ABZ | + | + | + | + | – | – | – | – |
| ABZ (parent drug) | + | + | + | + | + | + | + | + |
Fig. 3The proposed metabolic pathway of ABZ in H. contortus adults.
Fig. 4Changes in the relative amount of the main ABZ metabolites M3ABZ (ABZ.SO; Fig. 2a) and M8ABZ (ABZ-N-glycoside, Fig. 2b) in worm homogenates and medium from females and males of the susceptible ISE strain and resistant IRE strain. The data represent the mean ± S.D. (n = 3). IS = internal standard.
List of main peaks for RCB biotransformation samples detected by UHPLC-MS/MS with their retention times, theoretical values of [M+H]+ ions in ESI positive-ion mode, elemental composition, product ions, and description of present metabolites.
| tR [min] | Theoretical | Elemental composition | Description of metabolite formation | Product ions of [M+H]+, | Metabolite designation | |
|---|---|---|---|---|---|---|
| Phase I | Phase II | |||||
| 1.83 | 444.1435 | C18H25N3O8S | – | 282, 240, 208, 191, 159 | M1RCB | |
| 2.33 | 444.1435 | C18H25N3O8S | – | 282, 240, 208 | M2RCB | |
| 2.88 | 460.1384 | C18H25N3O9S | S-oxidation | 298, 266, 224 | M3RCB | |
| 5.22 | 298.0856 | C12H15N3O4S | S-oxidation | – | 266, 224, 159 | M4RCB |
| 5.65 | 428.1486 | C18H25N3O7S | Reduction of sulfoxide (-O) | 266, 234, 191 | M5RCB | |
| 6.16 | 428.1486 | C18H25N3O7S | Reduction of sulfoxide (-O) | 266, 234 | M6RCB | |
| 7.5 | 266.10 | C12H15N3O2S | Reduction of sulfoxide (-O) | – | 234 | M7RCB |
| 3.32 | 282.09 | C12H15N3O3S | – | – | 240, 208, 191, 159 | RCB (parent drug) |
Presence (+) or absence (−) of RCB metabolites in homogenates and medium of H. contortus females and males from ISE and IRE strains.
| Metabolite designation | Homogenate of | Medium | ||||||
|---|---|---|---|---|---|---|---|---|
| ISE | IRE | ISE | IRE | |||||
| Females | Males | Females | Males | Females | Males | Females | Males | |
| M1RCB | – | – | + | + | – | – | – | – |
| M2RCB | – | – | + | + | – | – | + | – |
| M3RCB | – | – | – | – | – | – | + | – |
| M4RCB | + | + | + | + | + | + | + | + |
| M5RCB | – | – | + | + | – | – | + | + |
| M6RCB | – | – | + | + | – | – | – | – |
| M7RCB | + | + | + | + | + | + | + | + |
| RCB (parent drug) | + | + | + | + | + | + | + | + |
Fig. 5The proposed metabolic pathway of RCB in H. contortus adults.
Relative amount of unchanged parent drugs in homogenate of H. contortus adults.
| Relative amount of unmetabolized parent drugs [%] | ||||
|---|---|---|---|---|
| ISE | IRE | |||
| Female | Male | Female | Male | |
| 79.5 ± 6.4 | 90.3 ± 1.0 | 58.5 ± 3.8 | 90.8 ± 8.0 | |
| 64.2 ± 2.4 | 81.2 ± 9.3 | 27.5 ± 3.9 | 72.6 ± 8.5 | |
| 89.3 ± 11.5 | 82.1 ± 17.5 | 87.4 ± 12.6 | 90.7 ± 6.2 | |
The sum of normalized peak areas of parent drug and all metabolites in each sample represent 100%. The data represent the mean ± S.D. from 3 parallels (n = 3).
Significant difference between females of the ISE and IRE strains, P < 0.05.